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Background: The major challenge in ABO-incompatible transplantation is to minimize antibody-mediated rejection.
Effective reduction of the anti-ABO blood group antibodies at the time of transplantation has made ABO-incompatible
kidney transplantation a growing practice in our hospital and in centers worldwide. ABO antibodies result from contact
with A- and B-like antigens in the intestines via nutrients and bacteria. We demonstrate a patient with fulminant
antibody-mediated rejection late after ABO-incompatible kidney transplantation, whose anti-A antibody titers rose
dramatically following Serratia marcescens sepsis.
Case presentation: A 58-year-old woman underwent an ABO-incompatible kidney transplantation for end-stage renal
disease secondary to autosomal dominant polycystic kidney disease. It concerned a blood group A1 to O donation.
Pre-desensitization titers were 64 for anti-blood group A IgM and 32 for anti-blood group A IgG titers. Desensitization
treatment consisted of rituximab, tacrolimus, mycophenolate mofetil, corticosteroids, immunoadsorption and
intravenous immunoglobulines. She was readmitted to our hospital 11 weeks after transplantation for S. marcescens
urosepsis. Her anti-A IgM titer rose to >5000 and she developed a fulminant antibody-mediated rejection.
We hypothesized that the (overwhelming) presence in the blood of S. marcescens stimulated anti-A antibody formation,
as S. marcescens might share epitopes with blood group A antigen. Unfortunately we could not demonstrate
interaction between blood group A and S. marcescens in incubation experiments.
Conclusion: Two features of this post-transplant course are remarkably different from other reports of acute rejection
in ABO-incompatible kidney transplantation: first, the late occurrence 12 weeks after kidney transplantation and second,
the very high anti-A IgM titers (>5000), suggesting recent boosting of anti-A antibody formation by S. marcescens.
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Bacteremia-induced anti-ABO antibodiesBackground
Both HLA and ABO blood group system determine the
risk of rejection in clinical organ transplantation. The
major challenge in blood group ABO-incompatible (ABO-i)
transplantation is to minimize antibody-mediated rejec-
tion (AMR). In recent years, ABO-i kidney transplantation
programs have been developed that minimize the risk
for AMR and show excellent graft survival. The key to* Correspondence: a.deweerd@erasmusmc.nl
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stated.success has been effective reduction of the ABO anti-
bodies prior to transplantation. This is usually achieved
by repeated plasmapheresis with or without the use of a
specific immunoadsorption procedure. A low concentra-
tion of ABO antibodies creates a window of opportunity
for graft acceptance by an incompletely understood im-
munological phenomenon called “accommodation” [1,2].
Within the first week after transplantation, AMR may
occur but these can usually be effectively reversed by
current standard AMR treatment protocols. Anti-ABO ti-
ters usually remain low after transplantation. ABO anti-
bodies are traditionally referred to as ‘natural occurring’,ral Ltd. This is an Open Access article distributed under the terms of the Creative
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immunization. For over more than half a century, evi-
dence is mounting that ABO antibodies most likely result
from contact with A- and B-like antigens in the intestines
via nutrients and bacteria, and develop early in childhood
[3,4]. Therefore, boosting of ABO antibody titers may
occur by infections with Gram-negative bacteria [5] and
could, at least theoretically, cause AMR of ABO-i kidney
transplants [6,7]. We present a case of a late fulminant
AMR of an ABO-i kidney transplant which may have been
triggered by Gram-negative bacteremia.
Case presentation
A 58-year-old woman underwent living unrelated ABO-i
kidney transplantation. Her medical history revealed hyper-
tension and autosomal dominant polycystic kidney disease,
for which she had been on peritoneal dialysis. She had never
been pregnant and never received any blood products.
The donor kidney came from her 59-year-old husband
and the HLA mismatch was 1-2-2 on A, B and DR loci re-
spectively. She had no current or historical panel reactive
antibodies. The donor blood group was A1 and recipient’s
O. ABO desensitization treatment consisted of rituximab
375 mg/m2 4 weeks before transplantation; tacrolimus
0.1 mg/kg BID, mycophenolate mofetil 1000 mg BID;
prednisone 20 mg once daily starting two weeks before
transplantation and immunoglobulines 0.5 mg/kg one day
preoperatively. Five plasmapheresis sessions, followed by
adsorption of anti-A antibodies with the Glycosorb® device
coated with synthetically derived blood group A antigen,
were performed in the week before transplantation. Her
anti-A titer was 64 (IgM) and 32 (IgG) before treatment
and decreased to 2 at the day before kidney transplant-
ation. The surgical procedure was complicated by peri-
transplant hematoma, for which erythrocyte concentrate
and platelet transfusions were given (of blood group O do-
nors). Immunosuppressive therapy after transplantation
consisted of tacrolimus 4 mg BID, mycophenolate mofetil
1000 mg BID and prednisone 20 mg once daily. Valgancy-
clovir for cytomegolovirus (CMV) prophylaxis was started
post-transplantation. Direct graft function was noted.
During admission, our patient experienced transient
diarrhea and was treated for urinary tract infection with
ciprofloxacin. Urine cultured Pseudomonas aeruginosa
and Serratia (S.) marcescens (both > 105 colony forming
units (cfu)). Before discharge, a routine biopsy on day 14
revealed normal renal parenchyma, with no signs of rejec-
tion. Staining for C4d on endothelial cells was positive,
which is often seen after ABO-i kidney transplantation
and by itself does not indicate rejection. Anti-A titers
remained low: one day post-operative the IgG titer was 2
and the IgM titer 8; at discharge, IgM titers were 1 and
IgG titers were < 2. Renal function improved to a serum
creatinine of 113 μmol/l at time of hospital discharge.Seven weeks post-transplantation, patient was readmitted
for fever and loose stools. She had developed new onset
diabetes mellitus, for which intravenous insulin was started.
Abdominal ultrasound revealed a swollen transplant with
signs of pyelonephritis with multiple micro-abscesses. A
10-day course of ceftazidime and ciprofloxacin was started
for suspected pyelonephritis as the urine culture identified
various uropathogens, not further specified.
Eleven weeks post transplantation, patient returned
to our emergency department with fever, tachycardia and
pain over the renal allograft. Serum creatinine had risen to
115 umol/l with a C-reactive protein of 163 mg/l. Ultra-
sonography of the transplant kidney showed no gross
abnormalities with normal renal vascular flow. Cultures
of blood, urine and sputum were drawn and imipenem/
cilastatine therapy was initiated. Only the blood culture
became positive for S. marcescens sensitive to imipenem.
In the next 5 days, serum creatinine increased further to
275 umol/l in combination with severe fluid retention. A
newly obtained transplant ultrasound disclosed non-
measurable diastolic blood flow. On the clinical suspicion
of rejection, a three-day-course of methylprednisolone
1000 milligram intravenous was initiated and a transplant
biopsy was performed. The kidney biopsy revealed AMR
type 3 Banff ’09, with extended hemorrhagic infarction
and positive C4d staining (Figure 1) [8]. The anti-A IgM
titer was >5000 and anti-A IgG titer 512. Transplantect-
omy was performed as a renal scintigraphy showed no
perfusion. A swollen and hemorrhagic kidney transplant
was removed and chronic intermittent hemodialysis was
initiated. A repeated anti-A titer one month later was 256
for IgM and 32 for IgG (Figure 2).
Experiments
We hypothesized that the (overwhelming) presence in
the blood of S. marcescens stimulated anti-A antibody for-
mation, as S. marcescens might share epitopes with blood
group A antigen. We chose to perform a hemagglutination
inhibition assay instead of direct (serum) agglutination
with bacteria, as the latter could occur because of possible
aspecific clotting. S. marcescens obtained from the blood of
our patient was frozen and stored until use. The thawed
sample was plated on a (blood group free) Trypticase Soy
agar (Becton Dickinson, USA) and grown at 37°C over-
night. Cultures were suspended in phosphate buffered
saline (PBS) and the concentration of bacteria in suspen-
sion was assessed using McFarland standards and plate
counting the following day. Bacterial suspensions with
concentrations ranging from 105 cfu/ml to 108 cfu/ml PBS
and a PBS control were then either kept at 4 degrees
Celsius, boiled, or sonicated. Subsequently, these different
S. marcescens suspensions were incubated with anti-A
plasma for 30 minutes at 37°C. Next, blood group A eryth-
rocytes 4% (Sanquin blood supply, The Netherlands) were
AB
C
Figure 1 Kidney transplant biopsy 12 weeks after ABO-incompatible kidney transplantation. A. Severe hemorrhage of the cortex and
congestion of the glomeruli and tubulointerstitial compartment, with only minimal influx of inflammatory cells. There is a thrombus in the arteriole of
the glomerulus. (H&E staining; original magnification 10×). B. Congestion of the glomerulus with fibrinoid necrosis of the arteriole. There is ischemia of
the tubuli. An artery shows a transmural inflammation, of both mononuclear cells and neutrophiles. (Periodic acid-Schiff-Diastase stain; original
magnification 20×) C. Positive staining of more than 50% of the peritubular capillaries and all the glomeruli. (Immunohistochemistry for C4d; original
magnification 10×).
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room temperature. A PBS control was added to con-
firm visual agglutination after addition of A erythrocytes.
We hypothesized that preincubation with a certain ‘thresh-
old’ amount of bacteria would prevent hemagglutination.
We extrapolated this experimental design from the
methods of Springer et al. who demonstrated interaction
between Gram-negative bacteria and anti-ABO antibodies
in 1961 [9] (see Discussion for more details). Antibody titer
changes were investigated as well: after centrifugation
the supernatant was stored at 4°C and anti-A titers were
measured the following day by adding A erythrocytes in
serial plasma dilutions and compared to the original titer.
Titers were described as the highest dilution at which
hemagglutination was still visible.
We also performed experiments of bacterial incubation
with human serum without addition of A erythrocytes,
before measuring a possible change in titer the following
day. In a parallel experiment, incubation with anti-A
plasma took place for 2 hours at room temperature (for
IgM binding).
Results
In the first experiment serum was pre-incubated with
unboiled bacterial suspensions in increasing concentrations.After addition of blood group A erythrocytes however, ag-
glutination was still observed. As pre-incubation with viable
bacteria did not result in inhibition of hemagglutination,
i.e. did not absorb antibodies form the serum, we also
measured a possible change in antibody titers. The ori-
ginal titer was diluted threefold with bacterial suspension
and A erythrocytes in a 1:1:1 ratio. However, compared to
the PBS control, pre-incubation with bacterial suspensions
did not lower the titer of anti-A plasma when A erythro-
cytes were added.
Subsequently bacterial suspensions were boiled for
2.5 hours to unmask antigens that theoretically may
have been hidden by the bacterial capsule. IgM titers
were reduced but only one-fold, which was regarded as
non-significant. When a surplus of bacterial suspension
(4,8 × 10e9 cfu/ml) was added, agglutination was still
present.
In the last set of experiments, bacterial suspensions
were boiled and centrifuged at higher speed (14000 rpm)
than the previous experiment to prevent loss of light an-
tigens, or sonicated to prevent denaturation of antigens.
Similar amounts of bacterial suspension were incubated
with or without A erythrocytes. However, both boiling
and sonication did not prevent agglutination compared
to PBS control.
* kidney transplantation December 20th
[---]         8 sessions of immuno adsorption from December 13th till 23th
A
B
Figure 2 Course of anti-A antibody titers before and after ABO-incompatible kidney transplantation. The anti-A IgM (A) and IgG (B) titers
were 64 and 32 respectively before pre-operative immunoadsorption (December 13th), decreased to 2/2 pre-operatively (December 20th) and
were 1/<2 at discharge. During AMR they increased to >5000/512, decreasing to 256/32 one month later (logarithmic scale).
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We demonstrate a patient with fulminant antibody-mediated
rejection after ABO-i kidney transplantation, whose anti-A
IgM titers rose dramatically following S. marcescens sepsis.
Two features of this post-transplant course are different
from other reports of acute rejection in ABO-i kidney
transplantation: first, the late occurrence of AMR 12 weeks
after kidney transplantation and second, the very high
anti-A IgM titers (>5000).
Long term patient survival has not been shown to be
significantly different between ABO-compatible and in-
compatible kidney transplant recipients [10]. However, a
higher risk of AMR exists, occurring mainly in the direct
postoperative period. In the 51 patients with detailed time
of onset of AMR in the literature, only 4 experiencedAMR 12 weeks or later after transplantation [11-19]. Of
all the 65 recipients of an ABO-i kidney allograft in our
center so far, 9 experienced AMR and 3 a combined AMR
and cellular rejection, all within three months except for
the patient presented in this case report [20]. The patho-
logical role of anti-ABO IgG versus IgM on the ABO-i
renal allograft is a matter of debate [7,12,21]. Takahashi hy-
pothesizes on two distinct types of AMR after ABO-i kid-
ney transplantation: he states that type I AMR is caused by
re-sensitization due to ABO-blood group antigens, occurs
early postoperative and is characterized by an IgG anti-
body rise. Type II AMR on the contrary is caused by pri-
mary sensitization due to ABO-blood group-associated
antigens. IgM titer rises more than IgG and it takes longer
for this type of AMR to develop [7]. He accompanies this
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O recipient receiving a blood group B renal allograft, ex-
perienced an AMR on postoperative day 19 during uro-
sepsis with Klebsiella pneumonia. IgM rose from 4 to 64
and IgG from < 2 to 4. The second example is a 68-year
old male blood group B recipient who received a blood
group A renal allograft. On postoperative day 9 his graft
was removed because of an untreatable AMR in the pres-
ence of Methicillin-resistant Staphylococcus epidermidis
pneumosepsis. His IgM titer rose from 2 to 512 and IgG
remained < 2 during the clinical course. We therefore hy-
pothesized that also this AMR had a different etiology
than re-sensitization by blood group A antigens: a Gram-
negative sepsis.
ABO antibodies are not ‘natural occurring’ and result
from contact with A- and B-like antigens in the intes-
tines via nutrients and bacteria [3,4]. ABO antibodies are
either absent at birth or present via placental transfer
and breastfeeding. Before the age of 3, the infant’s gut
becomes colonized with commensal bacteria expressing
A- and B-like antigens. The developing immune system
produces antibodies against the antigens not present on
its own erythrocytes. The continuing influence of gut
bacteria on ABO antibody formation is reflected in per-
manent detectable IgM titers, for example the IgM titers
measured in kidney transplant recipients before ABO-i
kidney transplantation. In 1969 Springer and Horton fed
23 very young infants (35 weeks or younger) and 14
adults killed Escherichia coli O86 [4]. It concerned blood
group A and O individuals, both healthy subjects as well
as patients with intestinal disorders: 16 children with diar-
rhea, 2 adults with ulcerative colitis and 2 adults with
colon carcinoma. The majority had a fourfold or greater
increase in anti-B antibodies after ingestion, infants more
than adults and diarrheic patients more than healthy con-
trols. Moreover, six out of seven infants without a base-
line titer had titers of 16 or greater after ingestion. In
the same paper, Springer demonstrated that anti-human
blood group A and B antibodies in chickens can be neu-
tralized by injecting live Escherichia coli O86.
Many Gram-negative bacteria with human blood
group activity are identified. For example Yi sequenced
the entire Escherichia coli O86 gene cluster and identi-
fied all the genes responsible for the blood group B-like
antigen biosynthesis [22].
There is more evidence that bacterial suspensions
are able to reduce anti-ABO titers by binding these
ABO antibodies to the bacteria: Springer et al. assessed
the blood group activity of 282 Gram-negative bacteria
[9]. Different bacterial suspensions were incubated with
series of human serum with minimal 4 agglutination titers
for two hours. Almost 50 percent of these 282 strains
exhibited anti-ABO activity. Bacteria with only one speci-
ficity far outnumbered those with two or all threeABO specificities, in which anti-O and anti-B were
predominant.
Strong evidence that gut bacteria are able to trigger
ABO antibody formation is reported by Daniel-Johnson
et al. [23]. He describes severe hemolytic transfusion re-
actions in two blood group B recipients of a blood group
A platelet donor. Although platelet transfusion is prefer-
ably performed ABO identical or at least blood group
compatible, the limited availability of matched platelet do-
nors makes platelet donation across ABO barriers a com-
mon practice. This is infrequently followed by hemolysis as
only a small amount of (ABO-i) donor plasma is present.
In contrast, in the by Johnson described blood group A
platelet donor the anti-B IgG titer rose to 16384 after taking
three tablets of probiotics per day. Furthermore, the solubi-
lized form of this probiotic was found to be able to reduce
the measured anti-B in plasma of a randomly chosen blood
group A donor threefold, from 64 to 8 after incubation at
room temperature in vitro.
In ABO-i solid organ transplantation the relation be-
tween sepsis and AMR is also reported. A pediatric ABO-i
kidney transplant recipient experienced biopsy-proven
AMR during pyelonephritis, with an increase in anti-B
titers to 64 and 128 for IgG and IgM, respectively [6].
Oya et al. report on an ABO-i living donor liver transplant-
ation with an anti-B titer rise during an intra-abdominal
hematoma infected with Serratia marcescens. Subsequently
thrombotic microangiopathy developed. The authors sug-
gest that interaction between the anti-donor ABO anti-
bodies and the endothelial cells of the graft played a
causative role in this microangiopathy [24]. Unfortunately,
in our case, we could not demonstrate an anti-A antibody
binding capacity of the S. marcescens strain isolated from
our patient. There are several possible explanations for
this. First, the Serratia colonies grew rather mucoid which
is an indication of a capsule. The capsule might have been
impermeable to ABO antibodies. However, even boiling
which has been presumed to remove the capsule, or sonic-
ation to unmask the bacterial cell wall expressing other
antigenic epitopes, did not change the results. Second,
the amount of bacteria might have been insufficient.
However, we also performed incubation with a very viscous
density without a change in titer. Third, assay temperature
might play a role. However, temperature was adjusted for
IgM antigen binding to room temperature and for IgG
antigen binding to 37°C and this did not result in inhib-
ition of agglutination. Fourth, the time for interaction
between anti-A antibodies and bacterial epitopes and sub-
sequently with A erythrocytes was shorter than in the ex-
periments carried out by Springer. In addition, Springer
and Horton describe in their methods the possibility of
‘non-agglutinating-in-saline’ ABO antibodies and their de-
tection with anti-human serum after immunizing chickens
with ABO antigens. We did not explore this possibility.
de Weerd et al. BMC Nephrology 2014, 15:31 Page 6 of 7
http://www.biomedcentral.com/1471-2369/15/31Next to S. marcescens sharing a comparable epitope
with antigen A, another explanation for the development
of antibody-mediated rejection during S. marcescens sepsis
exists. This might be a change in antigenicity of the A
antigen. S. marcescens was cultured in our patient’s urine
several times and subsequently in her blood. S. marcescens
is a Gram-negative bacillus and belongs to the family
of Enterobacteriaceae [25]. Mannose-sensitive pili of
S. marcescens are known to stimulate renal scarring [26].
This renal scarring could have hypothetically enhanced
changes in ABO antigenicity in the kidney graft.
Conclusion
ABO antibodies result from contact with gut bacteria. A
Gram-negative sepsis could theoretically boost anti-ABO
antibody formation. We demonstrated a patient whose anti-
A titers rose dramatically after Gram-negative sepsis, leading
to a type 3 antibody-mediated rejection. Despite comparable
incubation experiments in the literature, we could not
demonstrate an interaction between S. marcescens and
anti-A antibodies. Therefore it remains uncertain whether
bacteremia can be the cause of antibody-mediated rejec-
tion in ABO-i kidney transplantation.
Consent
The patient has died. Written informed consent was ob-
tained from the husband for publication of this Case re-
port and any accompanying images. A copy of the written
consent is available for review by the Editor of this
journal.
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